Classification of Gene Mutations in a Children’s Cancer May Point to Improved Treatments
Nov 10, 2014
CHOP and Penn Medicine experts are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations, setting the stage for a phase 3 clinical trial.